Dariohealth (DRIO) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Dariohealth in July 2026.
DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DarioHealth's stock with a target price of $5.67, indicating strong potential growth.
Financial Health
DarioHealth is showing strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring DRIO
The GLP-1 Insurance Gap Reshaping Weight Care in 2026
Cigna's decision to drop coverage for popular GLP-1 weight-loss drugs like Wegovy and Zepbound for its employees signals a potential shift in employer-sponsored healthcare. This policy change could drive significant demand toward affordable direct-to-consumer telehealth platforms and alternative digital weight management programs.
Published: 3 June 2026
Explore BasketObesity Drug Distribution via Telehealth Platforms Explained
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Published: 1 April 2026
Explore BasketRenal Therapy Stocks (Biopharma & Research) In Focus
Vertex Pharmaceuticals recently achieved significant late-stage trial success for its experimental kidney disease drug, paving the way for accelerated regulatory approval. This breakthrough spotlights a broader investment opportunity in biopharmaceutical companies and medical researchers developing innovative treatments for chronic renal conditions.
Published: 10 March 2026
Explore BasketOral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketWearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: 12 September 2025
Explore BasketAt-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: 1 September 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: 21 August 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: 19 August 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: 17 June 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: 17 June 2025
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
